Riskpilot← Back to searchSign inGet full accessFARMACEUTISK LABORATORIUM FERRING A/S
A/SActiveCVR 62664819Amager Strandvej 405Manufacture of pharmaceutical preparations · NACE 2120Est. 1956— employees
Revenue 2024
DKK -763K
+14% vs 2023
EBITDA margin
100.0%
-14% vs 2023
Equity ratio
-188.3%
Financial strength
Net profit 2024
DKK -4,9M
+39% vs 2023
| Revenue | DKK -763K | +14% |
| EBITDA | DKK -763K | -14% |
| Net profit | DKK -4,9M | +39% |
| Total assets | DKK 163,2M | +0% |
| Equity | DKK -307,2M | -2% |
| Employees | — | — |
Legal name
FARMACEUTISK LABORATORIUM FERRING A/S
CVR number
62664819
Legal form
Aktieselskab
NACE code
2120 · Manufacture of pharmaceutical preparations
Founded
2. januar 1956
Share capital
DKK 1.000.000
Employees
—
VAT registered
Yes
Audit selected
Yes
Last report
2024-12-31
Financial year
January – December
Signatory rights
Selskabet tegnes af to bestyrelsesmedlemmer i forening eller af et bestyrelsesmedlem og den administrerende direktør i forening.
Company purpose
Selskabets formål er tilvirkning og salg af lægemidler, specielt hormoner samt kemisk-tekniske produkter.
Address
Amager Strandvej 405
Phone
+4538765400
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | — | — | — | -670 | -763 |
| Staff expenses | -0 | -0 | -0 | -0 | -0 |
| EBITDA | 33 | -381 | -312 | -670 | -763 |
| Depreciation & amort. | -0 | -0 | -0 | -0 | -0 |
| EBIT | 33 | -381 | -312 | -670 | -763 |
| Net financials | -2 | -2 | -66.473 | -9.655 | -5.524 |
| Profit before tax | 31 | -383 | -66.785 | -10.325 | -6.287 |
| Tax | 7 | -84 | 24.861 | -2.266 | -1.383 |
| Net profit | 24 | -299 | -91.646 | -8.059 | -4.904 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 3.315 | 3.143 | 3.379 | 163.997 | 163.185 |
| Equity | -202.300 | -202.600 | -294.246 | -302.305 | -307.209 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 205.615 | 205.743 | 297.625 | 466.302 | 470.394 |
| Total debt | 205.615 | 205.743 | 297.625 | 466.302 | 470.394 |
EBITDA margin
-76300000.0%
This company
15.8%
Market median
-482911492% vs market
20202024
Equity ratio
-188.3%
This company
38.2%
Market median
-593% vs market
20202024
Return on equity
-490400000.0%
This company
18.4%
Market median
-2665217491% vs market
20202024
Net profit margin
-490400000.0%
This company
8.1%
Market median
-6054321088% vs market
20202024
Asset turnover
-0.00×
This company
1.12×
Market median
-100% vs market
20202024
Debt / equity
1.53×
This company
0.62×
Market median
-147% vs market
20202024
- Annual report 2024Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via CVR / Virk · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via CVR / Virk · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
MK Chief Executive Officer | Chief Executive Officer | 2016 |
| Former (7) | ||
JA Deputy | Deputy | 2004 – 2008 |
AJ Chief Executive Officer | Chief Executive Officer | 2008 – 2016 |
JV Audit | Audit | 1956 – 1994 |
ES Audit | Audit | 1956 – 1996 |
CK | Deputy | 2004 – 2008 |
FJ Management | Management | 2001 – 2001 |
BA Management | Management | 2001 – 2008 |
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Board of Directors | 2025 | |
| Chairman | 2025 | |
| Former (15) | ||
| Chairman | 1999 – 2022 | |
| Board of Directors | 1999 – 2001 | |
| Board of Directors | 1956 – 1996 | |
| Deputy Chairman | 2001 – 2001 | |
| Chairman | 2022 – 2023 | |
| Board of Directors | 2023 – 2025 | |
| Board of Directors | 2022 – 2023 | |
| Board of Directors | 2004 – 2008 | |
| Board of Directors | 2004 – 2008 | |
| Board of Directors | 1956 – 2008 | |
| Board of Directors | 2004 – 2008 | |
| Board of Directors | 2001 – 2001 | |
| Chairman | 2023 – 2025 | |
| Board of Directors | 1956 – 1992 | |
| Board of Directors | 2001 – 2022 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Individual | 100% | 100% | 2013 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of FARMACEUTISK LABORATORIUM FERRING A/S also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Jon Allan Wong Nørring | Deputy | 0 companies |
| Anker Jesper Haarhøj Hald | Chief Executive Officer | 0 companies |
| John Voigt | Audit | 0 companies |
| Erling Stæhr Lohse | Audit | 0 companies |
| Charlotte Karina Johansen | Deputy | 0 companies |
| Finn Jeppesen | Management | 0 companies |
| Bjarne Andersen | Management | 0 companies |
| Marianne Kock | Chief Executive Officer | 0 companies |
| Ole Kjerulf-Jensen | Chairman | 0 companies |
| Eva Wolf Paulsen | Board of Directors | 0 companies |
| Ellen Ingeborg Elise Hansen | Board of Directors | 0 companies |
| Christiaan Paul Thomas | Deputy Chairman | 0 companies |
| Per Gunnar Falk | Chairman | 0 companies |
| Curtis McDaniel | Board of Directors | 0 companies |
| Jens-Eric Regelin | Board of Directors | 0 companies |
| Lars Beck Madsen | Board of Directors | 0 companies |
| Michel Pettigrew | Board of Directors | 0 companies |
| Pierre-Jerome Blain | Board of Directors | 0 companies |
| Dag Frederik Arfst Paulsen | Board of Directors | 0 companies |
| Niels-Henrik Ebbe Andersen | Board of Directors | 0 companies |
| Jeffrey Douglas McConaghy | Chairman | 0 companies |
| Klaus Eberhard Wachsen | Board of Directors | 0 companies |
| Frank Christoph Lindenmann | Chairman | 0 companies |
| Frederik Paulsen | Board of Directors | 0 companies |
| Lars Peter Brunse | Board of Directors | 0 companies |